Shane Kovacs
Director of Finance/CFO at OLEMA PHARMACEUTICALS, INC.
Net worth: 5 M $ as of 2024-05-30
Profile
Shane William Charles Kovacs is currently the Director at Knopp Neurosciences, Inc. and the Chief Operating & Financial Officer at Olema Pharmaceuticals, Inc. He previously worked as the Director at Knopp Biosciences LLC, Managing Director-Health Care Investment Banking at Credit Suisse (Australia) Ltd., Director at PTC Therapeutics International Ltd., CFO & Head-Corporate Development at PTC Therapeutics, Inc., Associate at National Bank Financial, Inc., Head-Biotechnology at RBC Capital Markets, Inc., and Chief Financial & Business Officer at BlueRock Therapeutics LP.
Mr. Kovacs completed his undergraduate degree at Queen's University and holds an MBA from Richard Ivey School of Business.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-04-22 | 484,987 ( 0.87% ) | 5 M $ | 2024-05-30 |
Shane Kovacs active positions
Companies | Position | Start |
---|---|---|
OLEMA PHARMACEUTICALS, INC. | Director of Finance/CFO | 2020-05-31 |
Knopp Neurosciences, Inc.
Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | Director/Board Member | - |
Former positions of Shane Kovacs
Companies | Position | End |
---|---|---|
BlueRock Therapeutics LP
BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. The company is based in Cambridge, MA. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. BlueRock Therapeutics' lead clinical program, Bemdaneprocel (BRT-DA01), is in phase I clinical trials for Parkinson's disease. BlueRock Therapeutics was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG. Seth Ettenberg has been the CEO of the company since 2020. | Director of Finance/CFO | 2020-02-29 |
RBC Capital Markets, Inc.
RBC Capital Markets, Inc. Investment ManagersFinance Part of Royal Bank of Canada, RBC Capital Markets, Inc. provides investment advice. The company is based in Albany, NY. | Corporate Officer/Principal | 2018-08-31 |
Credit Suisse (Australia) Ltd.
Credit Suisse (Australia) Ltd. Investment Banks/BrokersFinance Credit Suisse (Australia) Ltd. (Credit Suisse Australia) is a broker/dealer firm headquartered in Sydney, Australia. The firm was founded in 1999 and is a subsidiary of Credit Suisse AG, which is owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Australia offers global securities sales, trading and execution, prime brokerage, underwriting, and comprehensive investment research for corporate and institutional investors. | Corporate Officer/Principal | 2013-04-30 |
PTC Therapeutics International Ltd. | Director/Board Member | - |
Knopp Biosciences LLC
Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | Director/Board Member | - |
Training of Shane Kovacs
Queen's University | Undergraduate Degree |
Richard Ivey School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
PTC THERAPEUTICS, INC. | Health Technology |
OLEMA PHARMACEUTICALS, INC. | Health Technology |
Private companies | 7 |
---|---|
Knopp Neurosciences, Inc.
Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | Health Technology |
Knopp Biosciences LLC
Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | Health Technology |
National Bank Financial, Inc.
National Bank Financial, Inc. Investment ManagersFinance National Bank Financial, Inc. (NBF) is a Canadian mutual fund manager headquartered in Montréal, Quebec. The firm was founded in 1902 and is a direct subsidiary of National Bank Acquisition Holding, Inc., ultimately owned by National Bank of Canada (TSX: NA). NBF is an integrated firm that combines retail advisory and brokerage services with institutional brokerage, investment banking, corporate finance and securities clearing services for third parties. | Finance |
Credit Suisse (Australia) Ltd.
Credit Suisse (Australia) Ltd. Investment Banks/BrokersFinance Credit Suisse (Australia) Ltd. (Credit Suisse Australia) is a broker/dealer firm headquartered in Sydney, Australia. The firm was founded in 1999 and is a subsidiary of Credit Suisse AG, which is owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Australia offers global securities sales, trading and execution, prime brokerage, underwriting, and comprehensive investment research for corporate and institutional investors. | Finance |
RBC Capital Markets, Inc.
RBC Capital Markets, Inc. Investment ManagersFinance Part of Royal Bank of Canada, RBC Capital Markets, Inc. provides investment advice. The company is based in Albany, NY. | Finance |
PTC Therapeutics International Ltd. | |
BlueRock Therapeutics LP
BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. The company is based in Cambridge, MA. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. BlueRock Therapeutics' lead clinical program, Bemdaneprocel (BRT-DA01), is in phase I clinical trials for Parkinson's disease. BlueRock Therapeutics was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG. Seth Ettenberg has been the CEO of the company since 2020. | Commercial Services |
- Stock Market
- Insiders
- Shane Kovacs